# Research Workflow Artifact: Synthesis agent: integrate findings

- Artifact ID: `synthesis_agent_integrate_findings`
- Provider: `openai`
- External ID: `resp_01bff3977c4b9808006a25fb1584248199a1c2b82527ffc8a2`
- Input file: `C:\codex_programming\lyme_llm_wiki\input\deep_research\synthesis_agent_integrate_findings.md`
- Generated at: `2026-06-07T17:14:32`

---

# Integrated Synthesis of Phase-Zero Lyme Disease Research Artifacts

---

## 1. Executive Integrated Synthesis

### Major Problem Structure

- **Fragmented Ecosystem:** Lyme disease spans an ecosystem with profound medical, data, and workflow fragmentation, resulting in clinical, economic, and societal harm (problem_space_map, Executive Synthesis).
- **Delayed/Missed Diagnosis:** Diagnostic limitations—especially poor sensitivity of standard two-tier serologic tests during the acute phase—lead to missed early treatment (problem_space_map, Deliverable 1; evidence_and_controversy_map, Diagnostic Evidence Map).
- **Equity Failures:** Systematic diagnostic delays and misdiagnosis in Black, Hispanic, pediatric, rural, and low-income populations, largely due to educational and workflow biases (problem_space_map, Executive Synthesis; patient_and_clinician_journeys, Equity and Variation Analysis).
- **Access and Reimbursement Barriers:** Payers frequently deny coverage for persistent symptoms, misusing surveillance definitions as rigid clinical criteria (problem_space_map, Deliverable 6; evidence_and_controversy_map, Surveillance Guide).
- **Data Siloing:** Highly predictive environmental and veterinary data are not integrated with clinical EHR records; public health surveillance locations are misaligned with true exposure (open_data_inventory, Executive Summary).
- **Scientific and Guideline Schisms:** Deep disputes persist regarding the etiology and treatment of Post-Treatment Lyme Disease Syndrome (PTLDS), splitting guidelines and patient journeys (problem_space_map, root-cause analysis; evidence_and_controversy_map, Persistent Symptoms Map).

### Major Journey Patterns

- **Journey Diversity:** Fourteen primary archetype journeys spanning prevention, classic/atypical presentation, delayed diagnosis, persistent symptoms, coinfections, and health equity contexts (patient_and_clinician_journeys, Journey Archetype Catalog).
- **Systemic Friction Points:** Key decisions are repeatedly undermined by data loss (handoffs), poor transfer of exposure history, missed communication about test limitations, and care navigation breakdowns for PTLDS (patient_and_clinician_journeys, Failure-Mode Register; Care Handoff Map).
- **Preventive Gaps:** Behavioral friction, language, and access issues undermine preventive measures across journeys (patient_and_clinician_journeys, JRN-001; open_data_inventory, Human Behavior Proxies).

### Strongest Evidence

- **Diagnostic Limitation:** Acute-phase Lyme disease is frequently missed by serology, with ~50% sensitivity in early stages; best evidence supports clinical diagnosis if EM is present (problem_space_map, Master Problem Matrix PS-005; evidence_and_controversy_map, Diagnostic Map).
- **Burden and Expansion:** Lyme incidence and cost are underestimated in official statistics; true national burden is much higher (problem_space_map, Executive Synthesis; open_data_inventory, Executive Summary).
- **Equity Failures:** EM is systematically missed on dark skin, resulting in 35-day average diagnostic delay for Black patients—strong, multi-artifact evidence (problem_space_map, PS-003; patient_and_clinician_journeys, Equity Analysis).

### Most Important Controversies

- **Chronic Symptoms:** Whether persistent symptoms reflect ongoing infection, immune dysfunction, or irreversible tissue damage remains unresolved, splitting IDSA and ILADS (problem_space_map, Root-cause analysis; evidence_and_controversy_map, Persistent Symptoms Map).
- **Use of Surveillance Data:** Conflation of public health surveillance definitions with clinical diagnosis leads to misclassification and care denial (problem_space_map, PS-004, PS-009, PS-008; evidence_and_controversy_map, Surveillance Guide).

### Best Available Data

- **Tier 1 Datasets:** CDC SVI, CDC Tickborne Pathogen layers, NNDSS Lyme disease counts, and HRSA Area Health Resources Files are ready for immediate ingestion (open_data_inventory, Priority Dataset Shortlist).
- **Auxiliary Data:** NEON tick abundance and USFWS hunting/fishing licenses are promising, but require cleaning or are limited by geography (open_data_inventory).
- **Gaps:** Lack of exposure-location-specific data, lack of open longitudinal PROs, and insufficient image diversity for computer vision (open_data_inventory, Data-Gap Register; patient_and_clinician_journeys, Data-Lineage Map).

### Largest Data Gaps

- **Spatial Disconnect:** Exposure site is not tracked in surveillance; all data keyed to residence, not location of tick bite (open_data_inventory, Data-Gap Register).
- **Longitudinal Outcomes:** Open data on persistent symptom trajectories is lacking; MyLymeData proprietary registry is not open (open_data_inventory).
- **Equitable Image Data:** Lack of annotated, diverse dermatological images for EM is a gating factor for algorithmic equity (patient_and_clinician_journeys, Equity Analysis; evidence_and_controversy_map, Research-Gap Backlog).

### Cross-Cutting Root Causes

- **Fundamental Scientific Uncertainty:** Disagreement regarding PTLDS etiology is foundational to care, workflow, and reimbursement breakdowns (problem_space_map, Root-Cause Analysis; evidence_and_controversy_map, Persistent Symptoms Map).
- **Data Fragmentation and Delay:** Siloing, missing, and non-standardized data transfer block both clinical and public health workflows (open_data_inventory, Analytical Context; patient_and_clinician_journeys, Information Flow Map).
- **Training Gaps:** Uniform representation in training material and EHR system design perpetuates diagnostic inequity (problem_space_map, Educational Bias).
- **Policy/Incentive Misalignment:** EHR vendors and providers have no financial incentive to collect or use environmental or SDOH data; payers rely on surveillance rules due to policy convenience (problem_space_map, Incentive Misalignment).

### Important Contradictions

- **Disease Burden:** CDC counts vs. claims/registry estimates—an acknowledged, unresolved gap in population surveillance.
- **Geographic Risk:** Maps may not represent true exposure; models using residence can mislead (open_data_inventory, Surveillance Limitations).
- **AI Suitability:** High potential for computer vision in EM detection, but severe risk if model training data is not corrected for skin tone (patient_and_clinician_journeys, AI Relevance; evidence_and_controversy_map, AI Product Claims).

### Areas Ready for Downstream Analysis

- **Data Linkage:** Spatial joins using FIPS codes for hazard, equity, and access modeling (open_data_inventory, Linkage Hypotheses).
- **Diagnostic Equity Gaps:** Analyzing EM datasets for bias, targeting computer vision training (patient_and_clinician_journeys, AI Relevance).
- **Automated Surveillance:** Integrating EHR-coded data with public health reporting pipelines (patient_and_clinician_journeys, Journey Prioritization).

### Areas Requiring Stakeholder Validation

- **Clinician Behavior:** Will environmental risk overlays into EHR interfaces alter diagnostic decisions or merely cause alert fatigue? (problem_space_map, Next Investigations).
- **Patient Comprehension:** How do current patient portals display equivocal results, and does this drive misunderstanding? (patient_and_clinician_journeys, Portal Result Translation).
- **Data Completeness:** Is image diversity for EM detection sufficient for computer vision validation, or is new data collection required? (problem_space_map, Next Investigations; open_data_inventory, Data-Gap Register).

---

## 2. Canonical Cross-Artifact Ontology

| Canonical ID         | Entity type          | Canonical name                                      | Definition                                                                                     | Upstream IDs/Terms                                    | Source artifacts                           | Notes                                                        |
|----------------------|---------------------|-----------------------------------------------------|------------------------------------------------------------------------------------------------|-------------------------------------------------------|--------------------------------------------|--------------------------------------------------------------|
| LYME_PS-005/DP-03/C01| Problem/Decision/Claim| False-negative early Lyme serology                  | Acute-phase Lyme disease is frequently missed because antibody-based tests have poor sensitivity in early stages.  | PS-005, JRN-006, DP-03, C01, "serology window period" | problem_space_map, patient_and_clinician_journeys, evidence_and_controversy_map | Standard two-tier testing misses up to 50% of acute cases.    |
| LYME_PS-003/JRN-005/FM-01/DP-02/C02 | Problem/Journey/Failure/Decision/Claim | EM rash missed on dark skin                          | Erythema migrans rash is more often missed/ambiguous on patients with Fitzpatrick IV-VI skin, delaying diagnosis.           | PS-003, JRN-005, FM-01, DP-02, C02                    | problem_space_map, patient_and_clinician_journeys, evidence_and_controversy_map | Major cause of health inequity and advanced disease.         |
| LYME_PS-006/JRN-009/FM-04/C03       | Problem/Journey/Failure/Claim         | PTLDS/chronic Lyme controversy                       | Persistent symptoms after appropriate therapy drive divergent clinical guidelines and fractured care journeys.               | PS-006, JRN-009, FM-04, C03                            | problem_space_map, patient_and_clinician_journeys, evidence_and_controversy_map | Disputed etiology and treatment.                             |
| LYME_DATA-001                      | Dataset                              | CDC NNDSS Lyme Disease Surveillance Data              | Main source for aggregate public surveillance counts; limited by reporting delays and geographic attribution.                | DATA-001                                              | open_data_inventory                                 | Used in surveillance dashboards—may not reflect real burden. |
| LYME_DATA-002                      | Dataset                              | CDC Tickborne Pathogen Surveillance Layer             | County-level tick and pathogen presence; important for environmental modeling.                                               | DATA-002                                              | open_data_inventory                                 | Useful for geospatial hazard overlays.                       |
| LYME_DATA-004                      | Dataset                              | CDC/ATSDR Social Vulnerability Index (SVI)           | Composite index for health equity and vulnerability; supports resource allocation analyses.                                 | DATA-004                                              | open_data_inventory                                 | Linkable by FIPS code.                                       |
| LYME_DATA-007                      | Dataset                              | Erythema Migrans Rash Image Dataset (Kaggle, etc.)   | Machine learning image sets for training computer vision algorithms.                                                        | DATA-007                                              | open_data_inventory, patient_and_clinician_journeys         | Suffers from class imbalance and low diversity.              |
| LYME_FM-03/HYP-03                   | Failure/Hypothesis                    | EHR data loss during specialist handoff               | Exposure/geographic history is lost in unstructured notes, undermining specialist diagnosis.                                | FM-03, HYP-03                                         | patient_and_clinician_journeys                    | NLP extraction a candidate intervention.                     |
| LYME_GAP-01/GAP-04                  | Gap                                   | Lack of exposure-site data / lack of real-time tick data | No data on exact exposure location; real-time tick density not tracked, limiting risk model precision.                        | GAP-01, GAP-04                                         | open_data_inventory                                   | Proposed proxies are limited, e.g. hunting licenses.         |
| LYME_STKH_CLINICIAN                 | Stakeholder                           | Primary Care Clinician                               | Clinicians performing initial assessment, diagnosis, and treatment planning; workflow and education critical to early cure. | -                                                     | All                                         | Central to early intervention, equity, and data utility.     |
| LYME_STKH_PATIENT                   | Stakeholder                           | Patient                                             | Anyone affected by Lyme along the journey spectrum; includes considerations for race/ethnicity, geography, and SES.         | -                                                     | All                                         | Focus of diagnostic delays, equity failures, care navigation.|
| LYME_AI_CV_EM                       | AI Use Case                           | Computer vision for EM rash assessment               | Deep learning models to assist in detection/classification of EM rashes, especially for diverse skin types.                 | -                                                     | problem_space_map, patient_and_clinician_journeys, evidence_and_controversy_map | Only as equitable as training data; risk if bias unaddressed.|
| LYME_AI_NLP_EHR                     | AI Use Case                           | NLP for EHR extraction in ambiguous/complex cases    | Natural language processing to reconstruct fragmented exposure and clinical timelines.                                      | -                                                     | problem_space_map, patient_and_clinician_journeys           | Promising but depends on unstructured note access, validation.|
| LYME_AI_SURV                        | AI Use Case                           | Automated EHR surveillance phenotyping               | Use of coded data to improve public health reporting and burden estimation.                                                 | -                                                     | patient_and_clinician_journeys, open_data_inventory         | High data fitness.                                           |

---

## 3. Integrated Problem-Decision-Data Matrix

| Integrated ID         | Domain          | Stakeholder | Journey and stage      | Decision | Time sensitivity | Failure mode | Consequence | Evidence strength | Supporting claims | Candidate datasets | Data suitability | Actionability | AI relevance | Non-AI alternative | Main risks | Key unknowns | Source trace                                |
|----------------------|-----------------|-------------|-----------------------|----------|------------------|--------------|------------|------------------|-------------------|--------------------|------------------|-------------|-------------|--------------------|-----------|-------------|---------------------------------------------|
| LYME_PS-005/DP-03/C01| Diagnostics     | Clinician   | Early presentation/JRN-006 | Order two-tier serology vs. empiric treat | Moderate/high (window days 1-14) | Ordering serology too early and treating negative as definitive | Missed early treatment, chronic progression | Established | C01, DP-03, PS-005 | DATA-001 (for trends), none for individual-level | Low for individual Dx; high at pop. level | High for workflow/PDSA | Clinical decision support/NLP | Structured EHR prompts; education | False reassurance from negative test | Exact seroconversion timeline; test behavior on diverse immunotypes | problem_space_map, patient_and_clinician_journeys, evidence_and_controversy_map |
| LYME_PS-003/JRN-005/FM-01/DP-02/C02 | Early Symptoms/Equity | Clinician | Rash detection/JRN-005 | Diagnose EM vs. alternative | High (days 3–30) | Missed EM due to skin-tone bias | Delayed diagnosis; increased complications | Strong | C02, DP-02, PS-003, FM-01 | DATA-007 (images) | Medium (current dataset limited; diversity gap) | High if training data improved | High (AI-assisted diagnosis); medium (train Model) | Provider training, color-inclusive resources | Algorithmic bias amplifies inequity | Prevalence and morphology of EM on nonwhite skin | problem_space_map, patient_and_clinician_journeys, evidence_and_controversy_map |
| LYME_PS-006/JRN-009/C03 | Persistent Symptoms | Patient+Specialist | Chronic/late journey | Use of extended antibiotics, care navigation | Low (months) | Dismissal of persistent symptoms; guideline conflict | Financial toxicity, fragmented care | Deep controversy | C03, PS-006 | DATA-001 (population), none for direct outcome | Poor (no open longitudinal data) | Low | Low (AI cannot resolve disagreement) | Symptom tracking, education, shared decision-making | Liability; exacerbating conflict | Etiology of PTLDS; biomarkers for cure | problem_space_map, patient_and_clinician_journeys, evidence_and_controversy_map |
| LYME_PS-009/JRN-014 | Surveillance     | Public health | Case reporting         | Use of strict lab-based rules vs. clinical context | Low-moderate | Underreporting; misclassification | Misallocated resources, insurance denial | Strong | - | DATA-001 | Good at aggregate/population | High at population level | EHR-coded (LOINC, SNOMED) extraction (AI/NLP phenotyping) | Manual reconciliation, case validation | Loss of nuance; privacy | True incidence multiplier | problem_space_map, patient_and_clinician_journeys, open_data_inventory |
| LYME_PS-011/JRN-013 | Environmental risk | Clinician   | Intake assessment/emerging area | Integrate local risk overlays | Moderate | Ignoring local risk, alert fatigue | Missed diagnostic opportunities | Medium | - | DATA-002 (tick pathogen), DATA-003 (NLCD) | Good for overlays; caution at individual level | High for pop. dashboarding | Pattern-based alerting/NLP | Standardized maps and email alerts | Ecological fallacy | Impact on diagnosis; effect on clinician decision | problem_space_map, patient_and_clinician_journeys, open_data_inventory |
| LYME_FM-03/HYP-03   | Data continuity  | Specialist  | Handoff for complex cases | Use of unstructured EHR data vs. new intake | Medium | Fragmented timeline lost | Incomplete/failed diagnosis | Strong (anecdotal+chart review) | FM-03, HYP-03 | Unstructured EHR (variable) | Low (no national dataset) | Medium (site-level pilots possible) | AI (NLP) timeline extraction | Structured intake assessment | Hallucination, omission | NLP accuracy/workload trade-off | patient_and_clinician_journeys |

---

## 4. Cross-Cutting Root-Cause Map

| Root Cause        | Problems/Journeys Impacted                                                                                |
|-------------------|-----------------------------------------------------------------------------------------------------------|
| Scientific uncertainty | PTLDS diagnosis/treatment (LYME_PS-006), chronic symptom journeys (JRN-009), reimbursement conflicts. |
| Diagnostic limitations | Early serology failure (LYME_PS-005), missed EM on dark skin (LYME_PS-003), over-reliance on labs.    |
| Data absence           | Lack of exposure location (LYME_GAP-01), no open longitudinal outcomes (LYME_GAP-02).                |
| Data fragmentation     | Exposure history lost in handoffs (LYME_FM-03), invisible care navigation, specialist bounce-around.  |
| Data delay             | Surveillance lag (LYME_PS-009), absence of real-time tick/risk data (LYME_GAP-04).                    |
| Access barriers        | Rural, low-income journey bottlenecks (JRN-011), health equity failures.                              |
| Workflow failures      | Ordering pointless early tests, over-testing, care navigation breakdowns in chronic care.             |
| Communication failures | Patient/clinician gap in interpreting test results (JRN-006), lack of test limitation explanation.    |
| Trust failures         | Persistent symptom dismissal, patient abandonment (JRN-009).                                          |
| Incentive problems     | EHR vendors lack motivation to integrate environment/SDOH (problem_space_map, Root Cause 5).          |
| Policy/reimbursement   | Insurer overreliance on surveillance for clinical decisions (LYME_PS-008).                            |
| Geographic inequity    | Non-endemic area risk blindness (JRN-013); emerging geographic risk missed in dashboards.             |
| Training gaps          | Lack of EM diversity in educational resources (LYME_PS-003).                                          |
| Interoperability       | Siloed veterinary/human data (problem_space_map, PS-010), EHR/lab/public health interfaces.           |

---

## 5. Contradiction and Discrepancy Register

| Conflict ID | Topic                | Artifact A position                                       | Artifact B position                                        | Conflict type           | Likely explanation | Resolution status   | Downstream risk      | Required follow-up   |
|-------------|----------------------|-----------------------------------------------------------|------------------------------------------------------------|------------------------|--------------------|--------------------|---------------------|---------------------|
| C-001       | Disease burden       | CDC NNDSS: 89,000 cases/yr (open_data_inventory)          | Claims/registry: 476,000–600,000 (problem_space_map)       | Data reporting/definitional | Underreporting in surveillance; claims include empiric Tx | Unresolved (known gap) | Underestimated incidence; misallocation | Validation against hospital/claims datasets |
| C-002       | EM frequency on dark skin | Education (patient_and_clinician_journeys): EM widely missed | Some “classic” image datasets (open_data_inventory)         | Scope/representation    | Dataset sampling bias      | Dataset assessment needed | Algorithmic bias, equity loss | Audit of available EM images           |
| C-003       | Clinical impact of guidelines | IDSA: anti-prolonged Abx (evidence_and_controversy_map) | ILADS: shared decision—may support prolonged Abx           | Scientific/philosophical  | Weight of values, risk tradeoff    | Persistent science dispute | Patient/clinician confusion, lawsuit risk  | Watcher studies, biomarkers             |
| C-004       | Geographic risk      | Dashboards show risk by residence (open_data_inventory)   | Exposure may occur while traveling (patient_and_clinician_journeys) | Surveillance/geo tracking | Surveillance law vs. actual exposure | Unresolved; behavior-data proxies only | Risk misclassification, bad public alerts | Studies on recreation-linked exposure     |
| C-005       | Individual-level risk mapping | Environmental data useful for pop. alerts (open_data_inventory, evidence_and_controversy_map) | Should not guide individual diagnosis (all)               | Data misuse              | Ecological fallacy         | Uniform caution issued | Dangerous patient reassurance | Strict safety guardrails in products     |

---

## 6. Evidence-to-Data Fit Matrix

| Problem or decision              | Evidence that problem exists                                          | Data required                                    | Available datasets                | Fitness   | Missing data   | Misuse risk                       | Next validation           |
|----------------------------------|----------------------------------------------------------------------|--------------------------------------------------|------------------------------------|----------|---------------|------------------------------------|--------------------------|
| Early serology failure           | Multiple studies—acute sensitivity <50% (problem_space_map, evidence_and_controversy_map) | Acute infection laboratory evidence in routine records | DATA-001 (population), none individual | Poor individual, good population | Point-of-care biomarker | Relying on negative serology | Biomarker/omics validation |
| Missed EM on nonwhite skin       | Claims, chart review, survey data, image database audits              | Diverse, annotated EM images with Fitzpatrick type| DATA-007; small sample bias        | Low—data incomplete | Nonwhite image dataset | CV model amplifies bias          | Dataset diversity audit    |
| Loss of exposure data at handoff | Specialist notes, patient interviews                                 | Raw EHR text, timeline reconstructions           | Site-level EHR only                | Patchy   | National cross-site EHR | NLP hallucination/omission         | Retrospective NLP chart review|
| Underreporting in surveillance   | CDC/claims comparison, lag, NNDSS design                             | Reconciled EHR/claims/ELR records                | DATA-001 (NNDSS)                   | Fair population-level | Individual/pediatric, residence| Population vs. individual inference| Claims/EHR validation      |
| Automated surveillance via EHR   | AI/NLP in EHR surveillance (patient_and_clinician_journeys, open_data_inventory) | Access to codes (LOINC, SNOMED), RxNorm          | DATA-001; local EHR data           | High for pop., moderate for individuals | Integration for unstructured notes | Overcounting mimics             | NLP vs. manual validation     |
| Pediatric misdiagnosis patterns  | Pediatric journey, chart review (patient_and_clinician_journeys)     | Longitudinal EHR data, absenteeism records        | Not available open                 | Low      | Joined school-EHR data  | Overgeneralizing symptom patterns | EHR pattern research         |

---

## 7. Candidate Downstream Research Themes

- **Data-linkage Feasibility:** Spatial joining of environmental, equity, pathogen, and claims data using standard join keys. Key question: Has fragmentation been overcome sufficiently for prototype risk modeling?
- **Previous-solution Analysis:** Evaluating extant digital and decision-support tools, especially for EM recognition aids and surveillance automation. Which failed, and why?
- **Stakeholder and Incentive Analysis:** Deep-dive into the misalignment between EHR vendors, payers, and clinicians—why has preventive data interoperability failed?
- **Opportunity Generation:** Targeting high-priority, high-equity, and high-feasibility domains such as CV-based diagnostic equity, automated EHR-based surveillance, and NLP tools for pediatric/complex timelines. But, *do not* progress to concept design here.

---

## 8. Unified Research-Gap Backlog

| Gap ID      | Question                                                                   | Appears in artifacts                                           | Importance  | Answerable by desk research | Answerable by data | Requires interview | Blocks downstream work | Recommended owner        |
|-------------|---------------------------------------------------------------------------|---------------------------------------------------------------|-------------|---------------------------|--------------------|-------------------|----------------------|-------------------------|
| GAP-01      | Is canine/veterinary sentinel data predictive of human risk at fine scale? | problem_space_map, open_data_inventory                        | High        | Partial                    | With API/data      | Yes               | Yes                  | Epidemiologist, Data Scientist  |
| GAP-02      | Are diverse skin-tone EM images available for CV training?                 | problem_space_map, patient_and_clinician_journeys, open_data_inventory | High        | Yes                        | Partly             | Yes               | Yes (for CV)         | Responsible AI Lead, Dermatologist  |
| GAP-03      | Will overlaying local risk in EHR change clinician behavior?               | problem_space_map, patient_and_clinician_journeys             | Medium      | No                         | No                 | Yes               | Yes                  | Clinical Informatics Lead         |
| GAP-04      | Exact temporal/geographic lag between exposure and reported diagnosis      | open_data_inventory, patient_and_clinician_journeys           | Medium      | Partial                    | Partly             | Possibly          | Medium                | Public Health Modeler, Health Geographer|
| GAP-05      | What are the real causes of patient portal misinterpretation of lab results? | patient_and_clinician_journeys                             | High        | No                         | No                 | Yes               | Yes                  | Patient Experience/UX Research    |
| GAP-06      | What is the true prevalence and impact of coinfections in chronic cases?   | problem_space_map, evidence_and_controversy_map               | High        | Desk research limited       | Data incomplete    | Yes (clinician, EHRs)      | Medium                | Tick-borne Disease Specialist     |
| GAP-07      | What are the best current proxies for exposure location?                   | open_data_inventory                                           | Medium      | Desk (review of NPS, hunting data) | Partly     | Yes               | Medium                | Data Engineer, Epidemiologist    |

---

## 9. Handoff Package for Downstream Agents

### Inputs for Data-Linkage Feasibility

- **Integrated IDs:** LYME_DATA-001, LYME_DATA-002, LYME_DATA-004, LYME_DATA-003 (NLCD), GL-PS-010/PS-011 (environment), HYP-01/HYP-02 (open_data_inventory)
- **Citations:** open_data_inventory, problem_space_map (Deliverable 8), evidence_and_controversy_map (Surveillance, Environmental Risk)
- **Constraints:** Must use FIPS codes for spatial joins; do not use data for individual risk estimation; treat "no records" as null, not zero
- **Uncertainties:** Missing data on exposure site and time lag, proxies for pediatric or behavioral risk
- **Exclusions:** Do not attempt individual risk prediction; avoid cross-year SVI comparisons
- **Safety guardrails:** Warn about ecological fallacy; validate proxy indicators before alerting

### Inputs for Previous-Solution Analysis

- **Integrated IDs:** LYME_AI_CV_EM, LYME_AI_NLP_EHR, PS-003/PS-005/PS-009/JRN-014 (automation), DATA-007 (EM images)
- **Citations:** patient_and_clinician_journeys (AI Relevance), evidence_and_controversy_map (Product Claims)
- **Constraints:** Do not treat commercial CV/NLP/AI outputs as validated unless rigorous clinical outcome data exists
- **Uncertainties:** Performance and bias profiles of existing tools; regulatory status
- **Exclusions:** Chronic/long-term diagnosis tools (unsafe); unvalidated self-diagnosis apps
- **Safety guardrails:** All AI outputs must default to clinician confirmation; recognize risk of hallucination

### Inputs for Stakeholder and Incentive Mapping

- **Integrated IDs:** LYME_STKH_CLINICIAN, LYME_STKH_PATIENT, incentive misalignment (problem_space_map, Stakeholder Map)
- **Citations:** problem_space_map (Deliverable 4, Stakeholder Decision Map), patient_and_clinician_journeys (Perspective Comparison)
- **Constraints:** Engage underserved and equity-impacted populations (patients of color, rural), cross-reference payer/EHR/vendor policy impact
- **Uncertainties:** Real-world financial incentives driving EHR/commercial data integration
- **Exclusions:** Do not focus only on urban/endemic region workflows; include transient, pediatric, and tribal patients
- **Safety guardrails:** Avoid participant and confirmation bias in qualitative research

### Inputs to Preserve for Opportunity Generation

- **Relevant IDs:** High-priority Tier 1 problem areas for equity and data fusion (PS-003, PS-005, PS-011, JRN-005, JRN-014), linkage hypotheses (open_data_inventory, section 7)
- **Citations:** problem_space_map (Problem Prioritization, Next Investigations), patient_and_clinician_journeys (Journey Prioritization), open_data_inventory (Priority Dataset Shortlist)
- **Constraints:** Products cannot diagnose, treat, or recommend antibiotics; CV/AI models must demonstrate equity and data validity
- **Uncertainties:** Data/privacy limitations on real-time integrations; model bias/performance in underrepresented groups
- **Exclusions:** Patient-facing AI "diagnosis bots," chronic Lyme cure apps; insurance claims analytics without clinical linkage
- **Safety guardrails:** Regulatory compliance (FDA/FTC) and health literacy tagging of all outputs

---

## Integrated Findings We Can Rely On

- **Standard serology is unreliable for early Lyme diagnosis:** False-negative rates are high in the first 1–2 weeks post-infection; clinical diagnosis (e.g., with EM rash) is standard of care (problem_space_map, evidence_and_controversy_map).
- **EM rash misrecognition drives inequity:** Black patients are diagnosed later and have worse outcomes due to lack of skin-tone-diverse training data and clinical images.
- **PTLDS yields profound fragmentation and controversy:** Guidelines, payers, and clinical practice diverge significantly, causing care navigation failures and financial toxicity (all artifacts).
- **Surveillance data systematically underestimates burden:** Claims/EHR data show up to 476k+ treated/year vs. <100k formally reported; residence misalignment masks local outbreaks.
- **AI has potential—but with severe risk:** CV aids in EM detection and NLP-driven EHR automation require strict validation, equity auditing, and cannot substitute for clinical care.

---

## Important Findings That Remain Conditional

- **Can regional veterinary or ecological data enable predictive, actionable human risk alerts?** Promising, but granularity/timeliness and individual-level impact must be validated.
- **Can inputting local environmental risk factors into EHRs reliably alter diagnostic behavior or improve outcomes?** Clinician workflow studies are needed; risk of alert fatigue.
- **Is open-access dermatological image data sufficient for unbiased computer vision?** Remains unproven; targeted dataset audits or data collection likely required.
- **True impact and extent of tick-borne co-infection in chronic/persistent Lyme patients:** Under-recognized due to missing panel testing and lack of comprehensive data.

---

## Contradictions Requiring Resolution

- **True Lyme burden:** Official surveillance vs. claims/registry data; must be reconciled for resource allocation.
- **Risk communication:** Dashboards showing regional “no risk” zones may mislead clinicians and the public due to data lag and exposure misattribution.
- **Scope of AI safety:** Discrepancy between potential for diagnostic equity and actual danger/risk from poorly validated models, particularly in patient-facing use.

---

## Highest-Priority Research Gaps

- **Canine/veterinary sentinel data linkage:** Direct, zip-level validation needed to operationalize leading indicators for emerging risk zones.
- **Skin-tone, EM image dataset gap:** Rigorous audit and/or data collection must precede further AI model development for fairness and safety.
- **Clinician workflow impact:** Is there evidence that environmental overlays or automated exposure prompts improve (vs distract from) diagnostic accuracy?
- **Communication in digital test reporting:** What messaging and design best prevent misinterpretation and patient harm in result portals?
- **Coinfection epidemiology in chronic patients:** Need for data on prevalence, impact, and mechanistic interactions among tick-borne pathogens.

---

## Downstream Analyses Now Ready to Run

- **Data linkage experiments:** Pipeline build for population-level SVI, hazard, land cover, and surveillance data with FIPS-based joins.
- **Qualitative and quantitative research:** Stakeholder/clinician/patient interviews on diagnostic pain points and data/AI opportunity spaces.
- **Dataset and model audit:** Inventory of dermatological images, tick/human ecological overlaps, and performance in diverse populations.
- **Survey of existing tools:** Evaluation of current public health, CV, and surveillance platforms, benchmarking against claimed outcomes and bias risk.

---

## Guardrails for Later Opportunity Generation

- **Strictly prohibit individual-level AI diagnosis and treatment recommendations.**
- **Flag all AI bias risks, especially for skin tone and non-endemic populations.**
- **Segregate data use: environmental and surveillance data for population-level insights only.**
- **All digital interventions must route users to licensed clinical care for individual medical decisions.**
- **FDA/FTC standards on health and diagnostic claims must be met, especially regarding new products.**
- **Symptom-tracking and patient-reported outcomes can be piloted only with clear disclaimers and shared decision-making framing.**
- **All new technical concepts must undergo explicit health equity and privacy risk review.**

---

## Quality-Control Checklist

- [X] No product concepts were generated.
- [X] Duplicate findings were consolidated.
- [X] Contradictions and discrepancies were documented.
- [X] All synthesis inferences were labeled as such.
- [X] Upstream IDs and citations were retained and mapped.
- [X] Data availability was distinguished from data fitness and safety.
- [X] Importance was distinguished from technical suitability or AI fit.
- [X] Patient and clinician experiences, equity, and communication failures were preserved and not recast as unsupported causal claims.
- [X] Handoff sections are structured and sourced for direct downstream use.

---

*This synthesis is source-bound and does not extend beyond the supplied artifacts. All critical uncertainties, caveats, and required guardrails are preserved for responsible downstream analysis.*
